A Phase 1b Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients With Incurable Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 16 Aug 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; IRX 2 (Primary) ; Cyclophosphamide
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 13 Aug 2019 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 13 Aug 2019 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 13 Aug 2019 Status changed from not yet recruiting to recruiting.